Author: Maheshwari Pandit

June 21 @ 2:00 pm – 8:30 pm In the ever-evolving landscape of the pharmaceutical industry, the quest for strategic locations that catalyse growth and innovation is more important than ever. Capitalising on geographical advantages, Bengaluru has become a hub for the lifesciences industry. The city is home to a considerable number of lifesciences companies, research institutions, and allied sector’s manufacturing units. As a gateway to Southeast Asia, it is facilitating cross-border trade and connecting businesses to emerging markets. Beyond logistics, the city’s temperate climate provides an ideal environment for pharma manufacturing and storage, ensuring the integrity and efficacy of products. Coupled…

Are you tired of wasting precious time logging in, navigating clunky interfaces, and searching for lost documents? Do you yearn for a document management system (DMS) that empowers effortless collaboration and keeps your information secure? Then buckle up, Greenbox users, because a revolution is brewing! We’re thrilled to announce a comprehensive update brimming with features designed to streamline your workflow, elevate user experience, and solidify Greenbox as the ultimate document management powerhouse. Let’s dive into the exciting new functionalities that will transform the way you organize, access, and collaborate on your documents. Effortless Access: Say Goodbye to Login Hassles Gone…

Daiichi Sankyo Europe’s Garth Virgin discusses post-COVID cardiovascular disease Why is CVD a key focus area for Daiichi Sankyo Europe?Aspiring to protect every life from cardiovascular disease (CVD) is a key focus at Daiichi Sankyo Europe – and a professional mission for me. The global pandemic highlights this in a way never seen before. Even prior to COVID-19, CVD was a high-profile challenge for the medical community as it was, and remains, Europe’s leading cause of death. On a personal note, CVD is a topic close to my heart, as I have experienced its impact personally in my own family…

Diversity of thought creates meaningful work Some say that diversity in the workplace feels like tokensim – promoting opportunities to simply tick a box. But that would be as ridiculous as a patient saying, “I’ve seen too many white doctors, I need to see a brown one next.” However, if a patient said, “can I get a second opinion?” it would be a completely appropriate request, because difficult situations can benefit from a diversity of thinking. This has relevance to all organisations but must be interpreted correctly. Diversity of thought requires people from all walks of life, not only because…

Rosemont Pharmaceuticals has been moving with the times for over 50 years In 1967, England were football’s reigning world champions (they really were), The Beatles were the biggest band in the universe and pretty much everyone – including dogs and cats – smoked. Make no mistake, things do change. In 1967, however, British pharma companies were pace-setting, treatment pioneers and the envy of the world. Evidently, some things never change. Indeed, throughout the 1960s, Britain witnessed a boom in innovative small-to-medium pharma companies, specialising in specific healthcare arenas, and driven by a mission to shake up the traditional treatment ecosystem.…

The lifelong autoimmune disease affects more than 150,000 people living in the UK A new King’s Doctoral Training Centre at the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King’s College London (KCL) has been launched to investigate symptom management for multiple sclerosis (MS) without using drugs. Funded by the MS Society, the new training centre will help treat symptoms including pain, sexual difficulties and psychological distress for MS patients who find it challenging to access non-drug treatments. Affecting more than 150,000 people in the UK, MS is a lifelong autoimmune disease that affects the brain and spinal cord. It…

The Medical Research Council (MRC) and pharmaceutical company AstraZeneca (AZ) have partnered to provide six MRC clinical fellows with industry placement opportunities for clinical research. As part of AZ’s BioPharmaceuticals Research and Development (R&D) business, the partnership aims to help the UK further foster clinical research. Currently, in the UK, the number of academic clinicians within the health system is predicted to decline and could make future clinical research more challenging. The scheme aims to provide currently MRC-funded clinically active healthcare professionals the opportunity to advance by further building regulatory experience and clinical processes involved in new medicines to strengthen…

Researchers from the University of Liverpool and Queen Mary University of London have demonstrated further evidence of the benefits of lung cancer screening across socioeconomic groups in a new study published in Lancet Regional Health Europe. Funded by the National Institute for Health Research’s Health Technology Assessment programme, the new evidence published also illustrates the importance of screening for individuals who live in areas of economic deprivation. Affecting around 40,000 people every year in the UK, lung cancer is currently the third most common cancer in the country and the leading cause of cancer worldwide, accounting for an estimated 1.8 million…

The Biotechnology and Biological Sciences Research Council (BBSRC) has invested £48m into the Babraham Institute, following a five-year review, to support core research on the key mechanisms that maintain the health of cells, tissues and organs. Over the next four years, the institute will receive funding to support research across epigenetics, immunology and cell signalling. The life sciences institute focuses on understanding biology in relation to maintaining health, particularly when protecting and maximising good health in the later years of life. From 2024 to 2028, the new BBSRC investment aims to support three strategic research programmes to advance the ability…

The Biotechnology and Biological Sciences Research Council (BBSRC) has invested £48m into the Babraham Institute, following a five-year review, to support core research on the key mechanisms that maintain the health of cells, tissues and organs. Over the next four years, the institute will receive funding to support research across epigenetics, immunology and cell signalling. The life sciences institute focuses on understanding biology in relation to maintaining health, particularly when protecting and maximising good health in the later years of life. From 2024 to 2028, the new BBSRC investment aims to support three strategic research programmes to advance the ability…